Latest Conference Articles

In the past 7 years, treatment for patients with non–small cell lung cancer has increased by over 100%, according to real-world data presented at iSPOR 2023.

An analysis of data from the CheckMate-648 trial sows that while adding nivolumab to either ipilimumab or chemotherapy for patients with advanced esophageal squamous cell carcinoma improves survival outcomes, their current price is not cost-effective for first-line treatment.

Study findings presented at iSPOR 2023 reveal a substantial economic burden related to metastatic non–small cell lung cancer care, which impacts both patients and the healthcare system.

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small cell lung cancer treated with cemiplimab.

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

Phase 1 data signals promise for botensilimab plus bastilimab for advanced ovarian cancer.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.

Bruno Bockorny, MD, discusses the findings from a study of botensilimab plus bastilimab for the treatment of patients with recurrent platinum refractory/resistant ovarian cancer.

Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.

According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.

Patients with advanced renal cell carcinoma showed positive improvements in survival and toxicity outcomes when given nivolumab monotherapy, salvage nivolumab, and ipilimumab.

In the PATRIOT-II study, patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance had a complete response rate of 13% and a partial response (PR) rate of 68%.

Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.

The phase 3 GRAPHITE study showed that vedolizumab plus standard prophylaxis after unrelated allogeneic hematopoietic stem cell transplantation was more effective vs placebo for the prevention of lower gastrointestinal graft-vs-host disease.

In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.

Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.

The phase 3 ZIRCON trial of 89Zr-DFO-girentuximab in clear cell renal cell carcinoma met its end point by exceeding high sensitivity and specificity thresholds.

Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.

Early data from the phase 2 CaboPoint trial shows a promising response rate among patients with advanced renal cell carcinoma that progressed after checkpoint inhibitor based combination therapy.

Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.

Early data of the Orca-T cellular therapy showed enough positive results from patients on the therapy to move on to a phase 3 study in this patient population.

Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.

A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.

The PARP inhibitor rucaparib bested physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer in the phase 3 TRITON3 study.

Treatment with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel is safe and effective for patients with relapsed/refractory multiple myeloma.